CN106137482B - A kind of nasal sinus stent and transport system - Google Patents
A kind of nasal sinus stent and transport system Download PDFInfo
- Publication number
- CN106137482B CN106137482B CN201510208438.3A CN201510208438A CN106137482B CN 106137482 B CN106137482 B CN 106137482B CN 201510208438 A CN201510208438 A CN 201510208438A CN 106137482 B CN106137482 B CN 106137482B
- Authority
- CN
- China
- Prior art keywords
- nasal
- nasal sinus
- spoke
- casing
- sinus stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
Abstract
The present invention relates to a kind of nasal sinus stents, extend along the longitudinal axis and are mounted with drug, the supporting rod of straight tube-like structure, which has top and free end, which is equipped with the clamping structure projected radially outwardly on the tube wall for close on free end；And it is sheathed on the casing on the supporting rod outer wall, the casing has connecting pin and the movable end of annular, the connected spoke of the more settings that are separated from each other is provided between the connecting pin and movable end, the top is fixedly connected with the connecting pin, and the movable end can be equipped in the clamping structure.The present invention also provides a kind of transport systems.The nasal sinus stent of the present invention realizes conveying in a contracted state, and is supported in diseased region in the deployed state, and treated using drug.
Description
Technical field
The present invention relates to a kind of extensible stents, relate more specifically to a kind of nasal sinus stent and transport system.
Background technology
Sclerotin chamber of the nasal sinus for multiple gassiness around nasal cavity, they are communicated with tubule with nasal cavity.The nasal cavity of normal person and
Epidermal mucosa cell in nasal sinus persistently has limpid liquid secretion to come out, then has rule rate via the cilium above mucosa cells
These secretion are flowed to nasopharyngeal cavity, throat from nasal sinus, via nasal cavity and swallowed again in esophagus and stomach by pulsation backward.General adult
People about secretes 1 liter of mucus daily, and the humidity inside nasal cavity and nasal sinus is maintained, while adsorb in air by these mucus
Dust and foreign matter, to protect the health of respiratory tract.Once because virus, the invasion of bacterium or the stimulation of foreign matter, cause limpid
Mucilage secretion become that purulence is thick or cilium forfeiture has the pulsation of rule rate, can all generate the feeling that the thick nasal mucus of purulence or nasal mucus are flow backwards,
And it is led to rhinitis or nose film swelling, it can all make these tubular occultations.When these tubular occultations, just influence whether that nasal cavity mucus is stagnant
Stream influences to discharge in nasal sinus.If not as good as morning diagnosis and treatment, will develop as nasosinusitis, allergic rhinitis or other rhinitis, sternly
There is nasal polyp in severe one.
Nasal polyp bilateral is multiple, unilateral less.Common symptom is grown up with polyp volume and is aggravated for duration nasal obstruction.Nose
Solinocrine object increases, when with sneeze, secretion can be serosity, mucus, such as concurrent sinus infection, and secretion can be purulence
Property.There is dysosmia more.Nasal obstruction severe one is spoken in rhinolalia clausa, and when sleep snores.Polyp base of a fruit elder can feel have in nasal cavity
Object is moved with breathing.Choanal polyp can cause exhale when intranasal expiratory dyspnea, if polyp block eustachian orifice, can cause tinnitus and
Dysacousis.Polyp obstruction nasal sinus drainage, can cause serious nasosinusitis, patient bridge of the nose, forehead and Face and cheek distending pain occurs not
It is suitable.
Nasal polyp in rhinoscopy in visible nasal cavity there are one or multiple surfaces are smooth, canescence, faint yellow or light red
Color such as the translucent swollen object of lichee meat-like.Tactile softness not bitterly, is not easy bleeding, interior no liquid, but loose connective group
It knits, color is dark red or pale, and with normal mucosa without apparent boundary, several cases are in addition to concha nasalis inferior almost without normal mucosa；CT is examined
It looks into and shows full group nasosinusitis, majority of cases concha nasalis media gas room disappears, and concha nasalis inferior is raised.MRI shows sinus mucosa centrality oedema, signal
Uniformly；It is recurred quickly after rotary-cut operation.The small person of polyp must shrink concha with vasoconstrictor or could be found with nasal endoscopes.Polyp
Big and more person, advancing can dash forward to prenaris, and front end by outside air and dust because often being stimulated, in pale red, table sometimes
There are ulcer and crust in face.Nasal polyp develops backward can dash forward to choana even nasopharynx.Huge nasal polyp can cause external nose to deform, nose
The back of the body broadens, and is formed " frog nose ".Visible thin slurry or sticky, purulent secretion in nasal cavity.
The therapy of nasal polyp has the methods of traditional nasal-cavity administration, functional endoscopic sinus surgery at present.
Nasal-cavity administration refers to that drug uses in nasal cavity, by the way that schneiderian membrance is stimulated to play topically or systemically therapeutic effect,
So as to reach a kind of outer treating method prevented and cured diseases.The nasal-cavity administration administering mode traditional as one is long-standing, in ear nose larynx
Section is generally used to treat various nasal cavities and disease of nasal sinus using extremely wide, can also be used as adjuvant drug for related with rhinopathy
Adjacent organs illness, played an important role in the process prevented and cured diseases in the mankind.But due to the resistance of intranasal tissue
Gear, active drug can not smoothly reach diseased region, therapeutic purposes are not achieved.
Functional endoscopic sinus surgery by the good illumination by endoscope and mating surgical instrument, can make
Operation becomes more fine.It is changed into traditional radical-ability or whole destructive operations for striking off mucous membrane in nasal sinus thorough
On the basis of removing lesion, retain the normal mucosa and structure of nasal cavity and nasal sinus as far as possible, form good ventilation and drainage, promote
The Functional operation for restoring nasal cavity, the form of sinus mucosa and physiological function.And it can be reached according to the severity of lesion
Rhinitis, nasosinusitis and the purpose of nasal polyp are cured by the recovery of nasal cavity and nasal sinus own physiological function.Due to its light conductivity
By force, multi-angle, the visual field are big, can directly pry through many significant points (such as each nasal sinus opening, each ditch, nasal sinus in nasal cavity
Internal hidden stenosis) and pharynx nasalis small lesions.In addition to operative treatment, camera shooting can be also carried out at the same time, preserves data, with
It is summarized for the consultation of doctors, teaching demonstration and scientific research.This method have many advantages, such as wound is small, in art and postoperative pain is small, operation is fine, but
It is expensive, the shortcomings of high recurrence rate.Operation excision polyp, Postoperative recurrent rate are 30%~50%, and average each patient will
1.5~4 operations of row, it is even more.And operation excision and change nose and nasal sinus treatment operation often to cut off it is all
Such as the anatomical structure of concha, nasal septum, nasal membrane etc..This kind of excision and reconstructive operation can be destroyed and be provided by these structures
Naturally filtering and humidification, lead to drying, bleeding, and incrustation increases the risk of infection, and smell is caused to change, including smelling
Feel decline, dysosmia, parosmia and anosmia.
Invention content
In order to solve the above-mentioned problems of the prior art, the present invention is intended to provide a kind of can accurately send drug to nasal cavity
Interior diseased region and directly act on this nasal sinus stent and drug transport system.
The present invention provides a kind of nasal sinus stent, which extends along the longitudinal axis and be mounted with drug, straight tube-like structure
Supporting rod, the supporting rod have top and free end, the supporting rod on the tube wall for close on free end be equipped with radially outward dash forward
The clamping structure gone out；And the casing on the supporting rod outer wall is sheathed on, which has connecting pin and the movable end of annular,
The connected spoke of the more settings that are separated from each other is provided between the connecting pin and movable end, the top is consolidated with the connecting pin
Fixed connection, the movable end can be equipped in the clamping structure.
Described sleeve pipe further includes the more free spokes extended from the connecting pin.
The connected spoke and the free spoke are alternately arranged.
The connected spoke is uniformly distributed along the circumferential direction of described sleeve pipe.
The clamping structure is the tongue piece projected radially outwardly of thermal finalization.
The clamping structure is uniformly distributed along the circumferential direction of the supporting rod.
The present invention also provides a kind of transport system, which includes connecting rod and push rod, wherein, the connecting rod connects
It is connected on above-mentioned nasal sinus stent, and pushing rod sleeve is set in the connecting rod.
The connecting rod is straight tube-like structure, has identical diameter with the supporting rod.
The push rod is the circular tube structure of both ends open, and the internal diameter of the push rod is more than the outer diameter of the connecting rod, described
The outer diameter of push rod is less than the internal diameter of described sleeve pipe.
The nasal sinus stent of the present invention utilizes the support force of casing, can be the tumour shape polyp of blocking nasal cavity with physical support
Mode squeezes, and diseased region is directly acted on using the drug loaded on the nasal sinus stent while nasal airflow is kept,
The slow release of long period can be even realized as needed, so as to which lesion locations are given with sustained drug treatment.The present invention
Nasal sinus stent realize conveying in a contracted state, and act on diseased region in the deployed state, the nose blocked to nasal polyp
Chamber plays a supportive role, and maintains the permeability of nasal cavity, similarly using the drug being carried on nasal sinus stent effectively to nasal polyp
It is treated in affected part.
Description of the drawings
Fig. 1 is that the nasal sinus stent of first embodiment according to the present invention is in the stereoscopic schematic diagram of unfolded state；
Fig. 2 is that the nasal sinus stent of first embodiment according to the present invention is in the stereoscopic schematic diagram of contraction state；
Fig. 3 is the stereoscopic schematic diagram of the supporting rod of the nasal sinus stent of first embodiment according to the present invention；
Fig. 4 is the enlarged drawing of the region A in Fig. 3；
Fig. 5 is that the casing of the nasal sinus stent of first embodiment according to the present invention is in the stereoscopic schematic diagram of contraction state；
Fig. 6 is the enlarged drawing of the region B in Fig. 5；
Fig. 7 is that the casing of the nasal sinus stent of first embodiment according to the present invention is in the stereoscopic schematic diagram of unfolded state；
Fig. 8 a are that the casing of nasal sinus stent according to the second embodiment of the present invention is in the stereoscopic schematic diagram of unfolded state；
Fig. 8 b are that the casing of nasal sinus stent according to the third embodiment of the invention is in the stereoscopic schematic diagram of unfolded state；
Fig. 9 is the stereoscopic schematic diagram of the transport system of first embodiment according to the present invention；
Figure 10 is the vertical of the connecting rod being connected on the nasal sinus stent of contraction state of first embodiment according to the present invention
Body schematic diagram；
Figure 11 is the vertical of the connecting rod being connected on the nasal sinus stent of unfolded state of first embodiment according to the present invention
Body schematic diagram；
Figure 12 is the stereoscopic schematic diagram of the push rod of first embodiment according to the present invention；
Specific embodiment
Below in conjunction with the accompanying drawings, presently preferred embodiments of the present invention is provided, and is described in detail.
Fig. 1-and Fig. 2 shows the nasal sinus stent 1 of first embodiment according to the present invention, which has when being unfolded
Lantern-shaped shape as shown in Figure 1, with cylindrical outer shape as shown in Figure 2 during contraction.Its center has one to extend along longitudinal axis L
Supporting rod 11 and the casing 12 being sheathed on 11 outer wall of supporting rod, the two is fixedly connected at one end.
For the structure of supporting rod 11 as shown in figure 3, the supporting rod 11 is straight tube-like structure, one end is the top affixed with casing 12
End 111, the other end are free end 112.On the tube wall of free end 112 is closed on, equipped with the clamping structure projected radially outwardly
113.As shown in figure 4, the clamping structure 113 is the tongue piece being formed on supporting rod tube wall in the present embodiment.I.e. in tube wall diameter
Wall surface (corresponding notch be 1131) is respectively cut to opposite both sides and forms the tongue piece 1132 that is connected on one side with tube wall, the tongue piece
1132 are fixed to project radially outwardly for example, by heat treatment process processing.The tongue piece is acted on when there is radially inward external force
When on 1132, which is radially-inwardly shunk and close incisions 1131 with connecting portion 1133 for shaft, so as to restore tubulose
Structure.In general, the outer diameter of the supporting rod 11 is 3mm-5mm, wall thickness 0.2mm-0.5mm, and the axial length of supporting rod 11 is
10mm-30mm.Clamping structure 113 is uniformly distributed along the circumferential direction of supporting rod 11, and quantity can be 2,3,4,5 or 6
It is a, preferably 2-3.
As shown in Figure 5-Figure 7, the both ends of the casing 12 are respectively connecting pin 121 and the movable end of annular to the structure of casing 12
122, the connected spoke 123 between connecting pin 121 and movable end 122 for the arrangement of circumferentially uniform intervals.The connected spoke
123 by between connecting pin 121 and movable end 122 uniform intervals cut tube wall and formed, make connected spoke adjacent to each other
There is gap between 123.As a result, casing 12 is tubular structure as shown in Figure 5 when not stressing, and by outer masterpiece
In the case of, the then radial outward dilations of connected spoke 123 form lantern-shaped structure as shown in Figure 7.In general, casing 12
Wall thickness is 0.2mm-2mm, and the quantity of connected spoke 123 can be 3-10 roots, and the width of connected spoke 123 is 1mm-2mm, length
For 25mm-50mm.Preferably, which can be formed by thin-wall pipes through rapid laser carving.
Fig. 1-Fig. 2 is returned to, top 111 is fixedly connected with connecting pin 121, such as can be bonded together with glue,
It can be welded to together, make between the two without relative motion.In unfolded state as shown in Figure 1,122 blocking of movable end
In on the tongue piece 1132 of supporting rod 11, at this point, connected spoke 123 is radially furthered out and so that casing 12 has major diameter
Profile, diameter at this time reach 8mm-25mm.In contraction state as shown in Figure 2, free end 112 is placed in casing 12
Portion, and the tongue piece 1132 of supporting rod 11 is in the circumferential in the gap between adjacent connected spoke 123, at this point, connection spoke
Item 123 is in nature overhang and casing 12 is caused to have the profile of minor diameter, and diameter at this time is about in 3mm-5mm.
The casing that Fig. 8 a give nasal sinus stent according to the second embodiment of the present invention is in the solid of unfolded state and shows
It is intended to, the both ends respectively connecting pin 121a of annular and movable end 122a of casing 12a, 121a and movable end in connecting pin
Connected spoke 123a between 122a for the arrangement of circumferentially uniform intervals.Connected spoke 123a by connecting pin 121a and
Uniform intervals cut tube wall and are formed between movable end 122a, make have gap between connected spoke 123a adjacent to each other.From
Connecting pin 121a also extends more free spoke 124a, between free spoke 124a is set between adjacent connected spoke 123a
In gap, i.e. connected spoke 123a and free spoke 124a are alternately arranged.In general, the wall thickness of casing 12a is 0.2mm-2mm, connection
The quantity of spoke 123a and free spoke 124a can be the width of 3-10 roots, connected spoke 123a and free spoke 124a respectively
It is 1mm-2mm, the length of connected spoke 123a is 25mm-50mm, and the length of free spoke 124a is than connected spoke 123a
The long 3mm-10mm of length.Under real use state, during the tail end of the separate connecting pin 121a of free spoke 124a can be at
The opening of concha and nasal septum, should due to the outer diameter of concha nasalis media and the hole of the opening of nasal septum more than movable end 122a
Flared tail end is more conducive to the outflow of nose liquid, and has stronger supporting role to concha nasalis media.
The casing that Fig. 8 b give nasal sinus stent according to the third embodiment of the invention is in the solid of unfolded state and shows
It is intended to, the both ends respectively connecting pin 121b of annular and movable end 122b of casing 12b, 121b and movable end in connecting pin
Connected spoke 123b between 122b for the arrangement of circumferentially uniform intervals.Connected spoke 123b by connecting pin 121b and
Uniform intervals cut tube wall and are formed between movable end 122b, make have gap between connected spoke 123b adjacent to each other.From
Connecting pin 121b also extends more free spoke 124b, between free spoke 124b is set between adjacent connected spoke 123b
In gap, a free spoke 124b and a connected spoke 123b are seamless between the two as one group, tightly get together.
That is connected spoke 123b and free spoke 124b are alternately arranged.In general, the wall thickness of casing 12b is 0.2mm-2mm, connected spoke
The quantity of 123b and free spoke 124b can be 3-10 roots respectively, and the width of connected spoke 123b and free spoke 124b is
The length of 1mm-2mm, connected spoke 123b are 25mm-50mm, and the length of free spoke 124b is longer than connected spoke 123b
Spend long 3mm-10mm.In addition, a series of fan groove 125b are carved on the top of connecting pin 121b, fan groove 125b is along the circumferential direction equal
Even distribution, radian are generally 5 ° -20 °, depth 0.5mm-3mm.After stent is unfolded, spoke bar upper end is close to connecting pin 121b's
Place can be by the pulling force of radial direction, and connecting pin 121b upper ends, due to the presence of fan groove 125b, can be connected by the pressure of radial direction
Connecing end 121b upper end diameters can become smaller, and lower end can become larger.Since up-small and down-big shape is presented in connecting pin 121b so that freely
Spoke 124b is there are one the trend expanded outwardly, and which enhances the support forces of free spoke 124b lower ends.
Fig. 9 shows the transport system of first embodiment according to the present invention, for that will be in the nasal sinus branch of contraction state
Frame is expanded to the nasal sinus stent in unfolded state, which includes connecting rod 2 and push rod 3, wherein, connecting rod 2 connects
In on nasal sinus stent 1, and push rod 3 is sheathed in connecting rod 2.
Figure 10 shows that connecting rod 2 is connected on the nasal sinus stent 1 of contraction state；And Figure 11 shows that connecting rod 2 connects
In on the nasal sinus stent 1 of unfolded state.As shown in Figure 11, which is straight tube-like structure, is had with supporting rod 11 identical
Diameter, specifically, the connecting rod 2 are connected to the free end 112 of supporting rod 11, it is preferable that the connecting rod 2 can be with supporting rod 11
It is integrally formed, carry out necessary wipe out when needing and removing connecting rod 2.It should be understood that connecting rod 2 and supporting rod 11
It is also feasible by internal thread connection.The axial length of the connecting rod 2 is 90mm-180mm.
Figure 12 shows the structure of push rod 3, the push rod 3 be both ends open circular tube structure, dimensionally, push rod 3 it is interior
Diameter is more bigger 0.01mm-0.1mm than the outer diameter of connecting rod 2, and the outer diameter of push rod 3 is more smaller 0.01mm-0.1mm than the internal diameter of casing 12.
With reference to Fig. 9-Figure 11, in specific transmission process, first, connecting rod 2 is connected to the free end of supporting rod 11
112, then push rod 3 from the free end of connecting rod 2 towards the direction of nasal sinus stent 1 is set in the outside of connecting rod 2, protected at this time
The position for holding connecting rod 2 is motionless, continues to move to push rod 3, and since the outer diameter of push rod 3 is more smaller than the internal diameter of casing 12, push rod 3 faces
The free end of nearly nasal sinus stent 1 will push movable end 122 to be moved along the outer surface of supporting rod 11 towards connecting pin 121, so as to
Cause 123 radial outward expansion of connected spoke, when movable end 122 reaches 1132 position of tongue piece, the movable end 122 is to this
Tongue piece 1132 applies radially inward external force, which radially-inwardly shrinks and be placed in notch 1131, and movable end 122 continues
It is moved towards connecting pin 121, after movable end 122 fully passes over notch 1131, such as passes through heat treatment process processing sizing
Tongue piece 1132 reverts to the state projected radially outwardly, withdraws from push rod 3 outward at this time, movable end 122 by 1132 blocking of tongue piece and
Casing 12 keeps unfolded state, as shown in figure 11.Finally, the connection between connecting rod 2 and supporting rod 11 is released.In reality
Under use state, the nasal sinus stent 1 in unfolded state is stayed in nasal cavity, is played a supporting role to being blocked caused by nasal polyp,
So as to make nasal cavity unobstructed.
In the present invention, nasal sinus stent can be formed, such as metal by nondegradable material, treated and completed in nasal polyp
Afterwards, the stent of the non-degradable material takes out from nasal cavity.Nasal sinus stent can also be formed by degradable material, such as can be dropped
Metal or Biodegradable polymer material are solved, after the completion of nasal polyp treatment, the stent of the degradation material can also be from
It takes out in nasal cavity, does not take out preferably, but gradually degrade in nasal cavity, ultimately produce water and carbon dioxide or small point
Son is discharged by nasal cavity.
Nasal sinus stent of the present invention can be process by materials such as stainless steel, cochrome, Nitinols, can also
By formation such as degradable metal such as magnesium, pure iron.Particularly magnesium alloy has been applied to cardiovascular specialist extensively recently, orthopaedics is planted
Enter the fields such as object.Magnesium alloy has relatively low corrosion potential, easily corrodes under the vivo environment containing chlorion, and with slow
Slowly the mode corroded is degradable in vivo, and corrosion product acts on organism nonhazardous, and participates in human homergy.
Nasal sinus stent of the present invention can also be made of degradable high polymer material, and high molecular material is by different polymerizations
Object or copolymer use different processing methods, degradation speed are adjusted such as forms such as blending, hollow or interlayers, with suitable
The demand for answering the treatment cycle of different sufferers different.
The Biodegradable polymer material is selected from one or more of following material：Degradable Polyurethane, it is degradable
Polyester, autohemagglutination (L- lactide-co-ds-lactide), poly- (L- lactide-co-ds, L- lactides), it is poly- (D- lactide-co-ds,
L- lactides), poly(lactide-co-glycolide), poly- (lactide-co -6-caprolactone), poly- (glycolide -co- 6-caprolactone),
Poly- (- diethyleno dioxide ketone of lactide-co), poly- (glycolide -co- diethyleno dioxide ketone), gather at poly- (lactide-co-trimethylene carbonate)
(glycolide -co- trimethylene carbonate), poly- (lactide-co-ethylene carbonate), poly- (glycolide -co- ethylene carbonate),
Poly- (lactide-co-propene carbonate), poly- (glycolide -co- propene carbonate), it is poly- (lactide-co -2- methyl -2- carboxyls -
Propene carbonate), poly- (glycolide -co- 2- methyl -2- carboxyls-propene carbonate), poly- (3-hydroxybutyrate ester -co- 4- hydroxyls
Butyrate), poly- (butyric ester -co- hydroxyl valerate), poly- (3-hydroxybutyrate ester -co- 3- hydroxyl valerates), poly- (4- hydroxyls
Base butyrate -co- 3- hydroxyl valerates), poly- (6-caprolactone -co- fumarate), poly- (6-caprolactone -co- fumaric acid the third two
Alcohol ester), poly- (lactide-co-ethylene glycol), poly- (glycolide -co- ethylene glycol), poly- (6-caprolactone -co- ethylene glycol), poly-
(the co- DETOSU-t-CDM of DETOSU-1,6-HD-), poly- (lactide-co-glycolide -co- 6-caprolactone), it is poly- (lactide-
Co- glycolide -co- trimethylene carbonate), poly- (lactide-co -6-caprolactone -co- trimethylene carbonate), it is poly- (second hand over
Ester -co- 6-caprolactone -co- trimethylene carbonate) and poly- (3-hydroxybutyrate ester -co- 3- hydroxyl valerate -co- 4- hydroxyls
Butyrate), lactide therein includes L- lactides, D- lactides and D, L- lactide.PVP, PVA, starch, biomolecule
(such as fibrin, fibrinogen, cellulose, collagen and hyaluronic acid), polyurethane, artificial silk, three acetic acid of artificial silk
Cellulose, cellulose, acetic acid, cellulose butyrate, acetylbutyrylcellulose, glassine paper, nitrocellulose, cellulose propionate are fine
Dimension element and carboxymethyl cellulose.
Particularly, polymer material of the Biodegradable polymer material for PLA and PGA (or PCL) blendings or copolymerization,
It can even is that the blending of two kinds of copolymers.On the one hand, such polymer have been widely used for intravascular stent, suture,
The three classes such as orthopaedics implant medical device product for many years, has better biocompatibility, avoids what some were caused by material
The generation of complication.In addition, according to clinical practice situation, setting has been carried out to the proportioning of material to reach support force and degradation week
The good collocation of phase.Wherein, mass percent shared in the polymer material of PGA and PLA blendings or copolymerization PLA can be
0%-85%, preferably 5-50%；Shared mass percent can be 0- in the polymer material that PCL is blended in PLA and PCL
50%, preferably 5-30%.More further, they can be the blending of two kinds of copolymers, such as：1090PLGA and 8515PLGA
It being blended, 1090PLGA and 9010PLGA is blended, and 8515PLGA and 5050PLGA is blended, and 1090PLGA and 7030PLC is blended,
Etc., it can so be used for producing the nasal sinus stent of different degradation times, meet the requirement of different support strengths, portioned product will
It is 1-3 months or so to seek support strength, can adjust to meet the requirements by the adjusting or blending ratio for being copolymerized proportioning.
Can polymer blend in addition to above-mentioned degradable polymer, further include synthesis and the polymerization of natural hydrolytic degradation
Object.Synthesis hydrolysis biodegradable polymer can include hydrolytic degradation polyester and include poly- (Pfansteihl-glycolic) (PLGA).
Typical natural biodegradable polymer includes chitosan.Typical water-soluble polymer includes poly(ethylene glycol) (PEG),
PEG block polymer, PEG/PLA and PEG polymer, PEG is random or alternate copolymer, such as polyethylene glycol/PLGA copolymers, sugarcane
Sugar, starch, algin, polyvinylpyrrolidone (PVP) and poly- (vinyl alcohol) (PVA).Poly- (N-acetyl-glucosamine) (crust
Element), poly- (ester), poly- (3-hydroxybutyrate ester), poly- (4 hydroxybutyric acid ester), poly- (hydroxybutyric acid-hydroxypentanoic acid), poly- (DL- third is handed over
Ester -co- caprolactone), poly- (glycolide is total to 6-caprolactone), poly(trimethylene carbonate), polyesteramide, poly- (glycolic-Sanya
Methyl carbonic), poly- (ether-ester) (for example, PEO/ polylactic acid), polyphosphazene etc..
Degradable polymer can even be blended with magnesium alloy, increase initial strength, but accelerate later stage degradation.
Nasal sinus stent of the present invention is mounted with drug, effectively nasal polyp affected part can be treated, and can root
It is sustained according to needing to realize.
The outer surface of nasal sinus stent of the present invention is loaded with drug.After nasal sinus stenter to implant, the medicine of rack outer surface
Object starts to discharge to the nasal wall and polyp contacted, it is suppressed that the regrowth of nasal polyp reduces the inflammation of nasal cavity.
The release of drug is adjusted according to the severity of nasal polyp, i.e. nasal polyp hyperplasia is very serious, then can increase
The dosage of drug, while extend the deenergized period of drug, for example drug release can be that release in -3 months 7 days finishes, it can also
6 months -1 years are extended to, while the material degradation characteristic for forming nasal sinus stent is also consistent with drug release accordingly.Together
When nasal sinus rack surface can also be coated with two or more different drugs, several drugs layered coated, release sequence presses layer
Release, after the drug release of the top, below drug be further continued for discharging.
Drug can be selected but be not limited only to drug set forth below：Long-acting steroids hormone, anti-inflammatory drug, antiallergic action
Medicine, parasympathomimetic, antihistaminic medicine, anti-infectious agent, antiplatelet drug, anticoagulation, antithrombotic, anti-scar medicine,
The congested agent of antiproliferative pharmaceutical, chemotherapeutic, antineoplastic, solution, accelerator for concrescence, vitamin are (such as：Retinoic acid, vitamin A, vitamin
B and its spin-off), immuno modulating agent, immunosuppressive drug and above-mentioned medicament composition or mixture.
Optional anti-infective medicament generally includes antiseptic, antifungal agent, antiparasitic agent, antivirotic, preservative.It is anti-
Scorching medicament generally includes steroids or nonsteroid anti-inflammatory drugs.
The antiallergy medicament that can be used for the present invention includes but are not limited to：Pemirolast Potassiu (
Santen, Inc.), Cetirizine Hydrochloride, levo-cetirizine hydrochloride and its any prodrug, metabolin, derivative, homology
Object, congener, growth, salt and their composition.The medicament of anti-malignant cell proliferation includes but are not limited to, actinomyces
Plain D, D actinomycin D IV, D actinomycin D I1, D actinomycin D X1, Dactinomycin, dactinomycin D (
Merck&Co.,Inc.).Antiplatelet drug, anticoagulant, antifibrin and antithrombase include but are not limited to, heparin
Sodium, low molecular weight heparin, heparan, hirudin, argatroban, Forskolin, Vapiprost, ring forefront element, class ring forefront
Element, glucan, D-Phe-Pro-arginine-chloromethane keto hydrochloride (chemical synthesis antithrombase), Dipyridamole, sugar
Protein I I b/III a platelet membranes receptor antagonist antibody, lepirudin 023 ludon, thrombin inhibitor (
Biogen, Inc.) and any medicine precursor, metabolin, derivative, homologue, congener, growth, salt and their combination
Object.
The cytostatics and anti-cell proliferation that can be used for the present invention include but are not limited to：Angiopeptin；Blood vessel is tight
Plain converting enzyme inhibitor, as captopril (Bristol-Myers Squibb
Co.), Cilazapril, lisinopril (Merck&Co.,Inc.)；Calcium channel blocking
Agent, such as nifedipine, colchicin；Fibroblast growth factor (FGF) antagonist, cod-liver oil (omega-fatty acid)；Histamine
Antagonist；Lovastatin (Merck&Co.,Inc.)；Monoclonal antibody includes but are not limited to, and blood is small
Plate derivative growth factor (PDGF) receptor specific antibody；Sodium nitroprussiate；Phosphodiesterase inhibitors；Prostaglandin inhibitor；Soviet Union
Lamine；Thrombocytin blocking agent；Steroids；Thio protease inhibitors；Platelet derived growth factor (PDGF) antagonist, including
But it is not limited only to, triazolo pyrimidine；Nitric oxide；And its any prodrug, metabolin, derivative, homologue, congener,
Growth, salt and their composition.
The antimicrobial agent that can be used for the present invention includes but are not limited to：Aminoglycoside, amphenicols, Ansamycin
Class, beta-lactam antibiotic, for example, penicillins, lincomycin class, macrolides, itrofurans, quinolones class,
Sulfonamides, sulfone class, Tetracyclines, vancomycin and their derivative and composition.It can be used for the branch of the application
The type agents of frame include but are not limited to：Amdinocillin, pivmecillinam, Amoxicillin, ammonia benzyl mould
Element, aspoxicillin, azidocillin, Bacampicillin, benzyl penicillinic acid, Benzylpenicillin sodium salt, Carbenicillin, carindacillin, clometocillin,
Cloxacillin, ciclacillin, dicloxacillin, Epicillin, fenbenicillin, flucloxacillin, hetacillin, Lenampicillin, Mei Tan
XiLin, Staphcillin sodium, mezlocillin, sodium nafcillin, oxacillin, penamecillin, penethacillin hydriodate, benzene
Bright penicillin, benzathine penicillin G, penicillin G benzhydrylamine, calcium benzylpenicillinate, hydrabamine penicillin G, scotcil, Pu Lu
Cacaine benzyl penicillin, penicillin N, penicillin, ospen, penicillin V benzathine, hydrabamine penicillin V, penimepicycline, benzene oxygen second
Base benzylpenicillin potassium, Pivampicillin, propicillin, quinacillin, sulbenicillin, Sultamicillin, Talampicillin, replaces Piperacillin
Amdinocillin, Ticarcillin.
The antifungal medicine that can be used for the present invention includes but are not limited to：Propylamine, imidazoles, polyenoid class, vulcanization
Carbamates, triazole type and its derivative medicament.Antiparasitic agent includes but are not limited to, Atovaquone, clindamycin,
Dapsone, double electric quinoline, metronidazole, pentamidinum, primaquine, pyrimethamine, sulphadiazine, trimethoprim/sulfamethoxazole, three
First Qu Sha and its mixture.
The antiviral agent that can be used for the present invention includes but are not limited to：Acyclovir, famciclovir, valacyclovir,
Edoxudine, Ganciclovir, phosphonic acid, cidofovir, Fomivirsen, HPMPA (9- (3- hydroxyl -2- phosphate methoxies propyl) -
Adenine), PMEA (9- (2- phosphate methoxies propyl)-adenine), HPMPG (9- (3- hydroxyl -2- phosphate methoxies propyl) -
Guanine), (1- (2- phosphate methoxy -3- hydroxypropyls)-born of the same parents are phonetic by PMEG (9- [2- phosphate methoxies propyl] guanine), HPMPC
Pyridine), Ribavirin, EICAR (5- acetenyls -1- β-D-RIBOSE base -1H- imidazoles -4- formamides), pyrazofurin
(3- [β-D-RIBOSE] -4- hydroxypyrazoles -5- formamides), look into 3- Chinese holly woods, GR-92938X (1- β-D-RIBOSE base -
1H- pyrazoles -3,4- diformamides), LY253963 (1,3,4- thiadiazoles -2- bases-cyanamide), RD3-0028 (1,4- dihydros -2,3-
Two sulphur of benzyl), ([3- aminobenzenes-N, N- bis- (2- carbamoylethyls)-sulfonic acid acyl are sub- by 4,4'- bis- [4,6-d] by CL387626
Amine] -1,3,5- triazine -2- base Amino-biphenvl -2-, 2'- sodium disulfonate), BABIM (two [5- amidino groups -2- benzimidazoles-l]-first
Alkane) NIH351 and its mixture.
The Cidex-7 agent that can be used for the present invention includes but are not limited to：Alcohol, chlorohexidene, the tincture of iodine, triclosan, six
Chlorophenol and silver-based agents：Such as silver chlorate, silver oxide, nano-Ag particles.
The anti-inflammatory class medicament that can be used for the present invention includes steroid and nonsteroidal anti-inflammatory agent.Applicable class is consolidated
Alcohol antiinflammatory drugs include but are not limited to, 21- acetyl oxygen pregnenolone, alclometasone, Algestone, Amcinonide, times chlorine
Meter Song, betamethasone, budesonide, Chloroprednisone, clobetasol, clobetasone, clocortolone, Cloprednol, cortisone, can
Pine, cortivazol, deflazacort, (11BETA,16ALPHA)-16,17-[methylethylidenebis(oxy), Desoximetasone, dexamethasone, diflorasone, diflucortolone, two pregna-fluorides
Butyl ester, enoxolone, fluazacort, Flucloronide, flumethasone, good fortune Buddhist nun shrinkage porosite, fluocinolone acetonide, fluocinolone acetonide acetate, Novoderm Varlane,
Fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, good fortune prednisolone, fludroxycortide, fluticasone propionate, aldehyde radical contracting
Pine, Halobetasol Propionate, Halometasone, halopredone acetate, Hydrocortamate, hydrocortisone, replaces according to carbon chlorine and sprinkles Halcinonide
Promise, depersolon, medrysone, meprednisone, methylprednisolone, Mo Meitasong furoates, paramethasone, prednicarbate,
Prednisolone, 25- diethylin Econopred, Inflamase, prednisone, prednival, Bo Nili
Fixed, Rimexolone, Tixocortol, triamcinolone, Triamcinolone acetonide, triamcinolone benetonide, haloperidone, triamcinolone hexacetonide,
And its derivative and composition.
The nonsteroidal anti-inflammatory agent that can be used for the present invention includes but are not limited to, epoxidase (cox) inhibitor.This
Class epoxidase (cox) inhibitor may include COX-1 or COX nonspecific inhibitors, for example, salicyclic acid derivatives, Ah Si
Woods, sodium salicylate, choline magnesium trisalicylate, salsalate, Diflunisal, salicylazosulfapyridine, Olsalazine；Para-aminophenol
Derivative, for example, paracetamol；Indoles and indeneacetic acid, for example, Indomethacin and sulindac；Iso-aryl acetic acid class, example
Such as, tolmetin, Diclofenac, ketorolac；Arylprop acids, for example, brufen, naproxen, Flurbiprofen, ketone group
Brufen, Fino ibuprofen, olsapozine；Anthranilic acid (that fragrant acid), for example, mefenamic acid, Meloxicam；Bmap acid
Class, for example, former times health class (piroxicam, Meloxicam)；Aldoketones, for example, Nabumetone.COX inhibitor may further include choosing
Selecting property cyclooxygenase COX2, for example, diaryl substituted furan ketone, rofecoxib；Diaryl substituted pyrazole class, celecoxib；
Heteroauxin class, e.g., Etodolac；Sulfonamides, e.g., aulin.
The chemotherapy and anti-tumor agents that can be used for the present invention include but are not limited to：Anticancer agent (e.g., chemotherapy of tumors
Medicine, biological response modifiers, angiogenesis inhibitor, hormone receptor blocking agent, low temperature therapy reagent and other can destroy
Or inhibit the medicament of tumour generation and growth), for example, alkylating agent or other can pass through DNA attacks directly kill cancer cell
Medicament (e.g., cycli phosphate amine, isoendoxan), nitroso ureas or other by inhibit cell DNA reparation kill cancer cell medicine
Agent (e.g., Carmustine (BCNU), lomustine (CCNU)), antimetabolite or other by interfere specific cells function prevent cancer
The medicament of cell growth, usually DNA synthesis (e.g., 6- mercaptopurines, 5 fluorodioxy pyridines (5FU), antitumor antibiotics and its
He can constrain or set DNA go forward side by side once prevent DNA synthesize compound (e.g., adriamycin, daunomycin, epirubicin, she
Up to than star, Mitomycin-C, bleomycin), plant (catharanthus roseus) alkaloid and other by plant extract anti-tumor agent comprising salmosin
(e.g., vincristine, vinblastine), steroid hormone, hormone inhibitors, hormone receptor antagonists and other can influence hormone
React growth of cancers medicament (e.g., tamoxifen, Trastuzumab, arimedex, e.g., the different dormancy of amino can and Formestane,
Triazole inhibitor, e.g., Letrozole and Anastrozole, steroid inhibitor, e.g., Exemestane), inhibit vascularization albumen, be small
Molecule, gene therapy and (or) other can inhibit neonate tumour blood vessel or the medicament of vascularization (e.g., meth-1, meth-2,
Sa Li polyamines), bevacizumab (Avastin), fish shark amine, endostatin, angiostatin, (cancer is stood by Angiozyme, AE-941
Disappear), CC-5013 (Revimid, a kind of thalidomide derivatives), medi-522 (Vitaxin), 2ME2
(2ME2, Panzem), carboxyltriazole (CAI), Kang Purui fourth A4 medicines precursors (CA4P), SU6668, SU11248, BMS-275291,
COL-3, EMD 121974, IMC-1C11, IM862, TNP-470, celecoxib (Celebrex Celebrex), rofecoxib are (big
Gram suitable Vioxx), interferon-' alpha ', interleukin 12 (IL-12) or it is any Science Vol.289,1197-1201 page (Aug.17,
2000) identified compound, these compounds are incorporated herein by reference.Biological effect adjust reagent (e.g., interferon,
BCG vaccine (BCG), monoclonal antibody, interleukin-22, granulocyte colony stimulating factor (GCSF) etc.), it is PGDF receptor antagonists, conspicuous
Sai Ting, asparaginase, busulfan, carboplatin, cis-platinum, Carmustine, Chlorambucil, cytarabine, Dacarbazine, pool is relied on
Glycosides, flucarbazonesodium, fluorouracil, gemcitabine, hydroxycarbamide, ifosfamide, Irinotecan, lomustine, melphalan, mercapto
Purine, methotrexate (MTX), thioguanine, phosphinothioylidynetrisaziridine, Raltitrexed, topotecan, bent fourth sulphur ester, vinblastine, vincristine,
Mitoazitrone, oxaliplatin, procarbazine, streptostacin, taxol, docetaxel, imuran, docetaxel spread out
Biological homologue, growth of these compounds and combinations thereof.
Above-described, only presently preferred embodiments of the present invention is not limited to the scope of the present invention, of the invention is upper
Stating embodiment can also make a variety of changes.What i.e. every claims applied according to the present invention and description were made
Simply, equivalent changes and modifications fall within the claims of patent of the present invention.The not detailed description of the present invention is
Routine techniques content.
Claims (7)
1. a kind of nasal sinus stent, which is characterized in that the nasal sinus stent extends along the longitudinal axis and is mounted with drug, including：
The supporting rod of straight tube-like structure, the supporting rod have top and free end, and the supporting rod is on the tube wall for closing on free end
Equipped with the clamping structure projected radially outwardly, the clamping structure cutting wall surface is formed and is connected with wall surface by connecting portion
Tongue piece, the tongue piece is by thermal finalization to project radially outwardly；And
The casing being sheathed on the supporting rod outer wall, which has connecting pin and the movable end of annular, in the connecting pin and work
The connected spoke of the more settings that are separated from each other is provided between moved end, the top is fixedly connected with the connecting pin, described
Movable end can be equipped in the tongue piece；
The length of connected spoke is 25mm-50mm；
When the connected spoke of casing is in nature overhang, casing has the diameter of 3mm-5mm, and tongue piece at this time is located at phase
In gap between adjacent connected spoke；When the movable end of casing is equipped on tongue piece, described sleeve pipe radial outward dilations are
The diameter of 8mm-25mm simultaneously provides the support force that the tumour shape polyp for blocking nasal cavity is squeezed in a manner of physical support；
Described sleeve pipe further includes the more free spokes extended from the connecting pin, and the connected spoke and the free spoke are handed over
For arrangement.
2. nasal sinus stent according to claim 1, which is characterized in that the connected spoke is along the circumferential equal of described sleeve pipe
Even distribution.
3. nasal sinus stent according to claim 1, which is characterized in that the clamping structure is equal along the circumferential direction of the supporting rod
Even distribution.
4. nasal sinus stent according to claim 1, which is characterized in that the nasal sinus stent is by degradable high polymer material structure
Into.
5. a kind of transport system, which is characterized in that the transport system includes connecting rod and push rod, wherein, the connecting rod connection
According on the nasal sinus stent described in any one of claim 1-4, and pushing rod sleeve is set in the connecting rod.
6. transport system according to claim 5, which is characterized in that the connecting rod is straight tube-like structure, with the branch
Strut has identical diameter.
7. transport system according to claim 5, which is characterized in that circular tube structure of the push rod for both ends open, institute
The internal diameter for stating push rod is more than the outer diameter of the connecting rod, and the outer diameter of the push rod is less than the internal diameter of described sleeve pipe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510208438.3A CN106137482B (en) | 2015-04-27 | 2015-04-27 | A kind of nasal sinus stent and transport system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510208438.3A CN106137482B (en) | 2015-04-27 | 2015-04-27 | A kind of nasal sinus stent and transport system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106137482A CN106137482A (en) | 2016-11-23 |
| CN106137482B true CN106137482B (en) | 2018-06-29 |
Family
ID=57346590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510208438.3A Active CN106137482B (en) | 2015-04-27 | 2015-04-27 | A kind of nasal sinus stent and transport system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106137482B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913952B (en) * | 2017-02-21 | 2020-08-25 | 东华大学 | Single-yarn medical multifunctional nasal plug and preparation method thereof |
| CN107440762B (en) * | 2017-07-27 | 2018-08-31 | 北京大学第三医院 | Nasal cavity holder and its manufacturing method |
| CN107714243B (en) * | 2017-09-29 | 2021-05-07 | 依奈德医疗技术（上海）有限公司 | Self-expansion type nasal stent |
| CN107753162B (en) * | 2017-09-29 | 2020-05-01 | 依奈德医疗技术（上海）有限公司 | Self-expanding intra-nasal stent assembly |
| CN107693176B (en) * | 2017-09-29 | 2021-01-05 | 依奈德医疗技术（上海）有限公司 | Sacculus expanding type nasal internal support |
| CN109106483B (en) * | 2018-07-18 | 2020-12-18 | 浦易（上海）生物技术有限公司 | Nasal sinus support |
| CN109199655A (en) * | 2018-08-28 | 2019-01-15 | 杨海弟 | It is a kind of hemostasis and medicament slow release art in nasal sinus bracket |
| CN109758278B (en) * | 2019-01-27 | 2020-12-04 | 乐畅医疗器械(上海)有限公司 | Self-expansion nasal sinus support and taking and placing device thereof |
| CN117137700B (en) * | 2023-10-30 | 2023-12-29 | 江苏启灏医疗科技有限公司 | Nasal sinus support and conveying system |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059193A (en) * | 1989-11-20 | 1991-10-22 | Spine-Tech, Inc. | Expandable spinal implant and surgical method |
| CN1729029A (en) * | 2002-09-18 | 2006-02-01 | 迅息Pty有限公司 | Nasal cavity dilator |
| US7803150B2 (en) * | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
| CN102573981A (en) * | 2009-05-15 | 2012-07-11 | 因特尔赛克特耳鼻喉公司 | Expandable devices and methods therefor |
| CN104398328A (en) * | 2014-09-30 | 2015-03-11 | 浦易（上海）生物技术有限公司 | Completely-depredated medicine carrying nasolacrimal stent and implantation system thereof |
| US8998986B1 (en) * | 2013-07-05 | 2015-04-07 | Zdzislaw B. Malinowski | Nasal stent |
| CN204766053U (en) * | 2015-04-27 | 2015-11-18 | 浦易（上海）生物技术有限公司 | Nasal sinus support and conveying system |
-
2015
- 2015-04-27 CN CN201510208438.3A patent/CN106137482B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059193A (en) * | 1989-11-20 | 1991-10-22 | Spine-Tech, Inc. | Expandable spinal implant and surgical method |
| CN1729029A (en) * | 2002-09-18 | 2006-02-01 | 迅息Pty有限公司 | Nasal cavity dilator |
| US7803150B2 (en) * | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
| CN102573981A (en) * | 2009-05-15 | 2012-07-11 | 因特尔赛克特耳鼻喉公司 | Expandable devices and methods therefor |
| US8998986B1 (en) * | 2013-07-05 | 2015-04-07 | Zdzislaw B. Malinowski | Nasal stent |
| CN104398328A (en) * | 2014-09-30 | 2015-03-11 | 浦易（上海）生物技术有限公司 | Completely-depredated medicine carrying nasolacrimal stent and implantation system thereof |
| CN204766053U (en) * | 2015-04-27 | 2015-11-18 | 浦易（上海）生物技术有限公司 | Nasal sinus support and conveying system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106137482A (en) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106137482B (en) | A kind of nasal sinus stent and transport system | |
| US20230046852A1 (en) | Expandable devices and methods therefor | |
| CN102988122B (en) | Prosthetic system for treating nasosinusitis or allergic rhinitis | |
| US10391204B2 (en) | Free-standing biodegradable patch | |
| US10159768B2 (en) | Multi-layer biodegradable device having adjustable drug release profile | |
| CN101945621B (en) | Self-expanding devices and methods therefor | |
| EP2298318A1 (en) | Device and methods for treating paranasal sinus conditions | |
| CN107427668A (en) | The air bag of drug coat | |
| CN102988299B (en) | Formation method of drug coating and drug coating prepared by same | |
| JP2024060025A (en) | Expandable member systems and methods for drug delivery - Patents.com | |
| CN204766053U (en) | Nasal sinus support and conveying system | |
| CN204951924U (en) | A slowly -releasing medicine support for nasal cavity | |
| CN106344232A (en) | Sustained release medicine bracket for nasal cavity, forming method and application thereof | |
| CN110141559A (en) | It is a kind of for the pastille slow-release particle of schneiderian membrane and its application | |
| EP3897806A1 (en) | Systems and methods for forming a customized therapeutic support | |
| Ng | Studies of biodegradable drug-eluting tracheal stents | |
| AU2015201043A1 (en) | Expandable devices and methods therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201203 room 218, innovation park of traditional Chinese medicine, No. 199, GuoShouJing Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee after: Puyi (Shanghai) Biotechnology Co.,Ltd. Address before: 201203 room 218, innovation park of traditional Chinese medicine, No. 199, GuoShouJing Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee before: PUYI (SHANGHAI) BIOTECHNOLOGY Co.,Ltd. |